2024-10-20 - Analysis Report
## AMGN Stock Analysis Report

**Company Overview:** Amgen Inc. is a leading biotechnology company developing and delivering innovative therapies for serious illnesses.

**Performance Analysis:**

**1. Relative Performance:**
* **Cumulative Return:** AMGN has a cumulative return of 79.88%, while VOO (S&P 500) has a return of 137.88%. 
* **Performance Gap:** AMGN lags behind VOO by -58.0%. This places AMGN in the 28.12 percentile of its historical performance against the S&P 500, indicating a relative underperformance.

**2. Recent Price Movement:**
* **Closing Price:** $321.66
* **5-Day Moving Average:** $322.87
* **20-Day Moving Average:** $322.45
* **60-Day Moving Average:** $326.54
* **Analysis:** The stock is trading slightly below its 5-day and 20-day moving averages, indicating a potential short-term downward trend. However, the 60-day moving average remains higher, suggesting some underlying strength.

**3. Technical Indicators:**
* **RSI:** 49.12 (Neutral). The RSI is currently neutral, indicating neither overbought nor oversold conditions.
* **PPO:** 0.06 (Slight Bullish). A positive PPO suggests a potential bullish trend, but the value is relatively low, indicating a weak bullish signal.
* **Delta_Previous_Relative_Divergence:** -14.19 (Short-Term Downward Trend). This indicator suggests a recent downward trend in relative strength, with a significant decline over the past 20 days.
* **Expected Return:** 0.0%. The expected return for AMGN is projected to be similar to the S&P 500 over the long term (2 years or more), indicating potential for modest returns.

**4. Recent Earnings and Outlook:**

| Date       | EPS  | Revenue  |
|-------------|------|----------|
| 2024-08-07 | 1.39 | $8.39B |
| 2024-05-03 | -0.21 | $7.45B |
| 2023-10-31 | 3.23 | $6.90B |
| 2023-08-04 | 2.58 | $6.99B |
| 2024-08-07 | 2.58 | $6.99B |

* **Analysis:** The latest earnings report for the quarter ending August 2024 shows an EPS of 1.39, exceeding analysts' expectations. However, the company has faced some challenges in recent quarters, with a negative EPS in the quarter ending May 2024. This suggests potential volatility in earnings performance. Overall, the company's revenue remains strong and its pipeline of new drugs continues to offer potential for future growth. 

**5. News and Recent Issues:**

* **Recent Market Outlook:**  The current market sentiment surrounding AMGN is mixed. While some analysts remain optimistic about the company's long-term growth prospects, others express concerns about the competitive landscape and potential regulatory hurdles. 
* **Analyst Opinions:**  Analysts' price targets for AMGN vary, with some suggesting a higher potential for growth while others are more conservative. This diversity reflects the mixed outlook for the company's future performance. 
* **Performance Highlights:**  AMGN has seen some recent success with its newer drugs and therapies, but it has also faced challenges with pricing pressures and competition in the market.

**6. Overall Analysis:**

AMGN's recent performance has been mixed, with some positive earnings results but also recent challenges. The stock is currently trading below its short-term moving averages, suggesting a potential downward trend. However, the long-term outlook remains promising, with a strong revenue stream and a pipeline of new drugs. 

**7. Key Considerations:**

* **Market Volatility:** The current market environment is volatile, and investors should be cautious about potential short-term fluctuations in AMGN's price.
* **Competition:** The biotechnology industry is highly competitive, and AMGN faces significant challenges from other companies.
* **Regulatory Landscape:** Regulatory approvals for new drugs can be unpredictable and pose a significant risk for biotechnology companies.

**Recommendation:**

While AMGN's long-term prospects remain positive, the current market conditions and recent performance data suggest a wait-and-see approach. Investors considering AMGN should carefully analyze the company's future prospects and assess the risks involved before making an investment decision.
